Crinetics Pharmaceuticals, Inc. CRNX
- PALSONIFY — Acromegaly Approved
- PALSONIFY — Carcinoid Syndrome Phase 3
- CRN09682 — Neuroendocrine Tumors Phase 1
- CRN09682
Home › Targets › somatostatin receptor 2
somatostatin receptor 2 (1 companies · 4 programs)
Companies with an active program directed at somatostatin receptor 2.